Would you continue immune checkpoint inhibitor therapy in a metastatic NSCLC patient with CNS failure if the systemic disease is otherwise controlled?
Does the extent/duration of systemic disease control (complete response vs. stable disease, for example) influence your decision? What about whether this is in the first-line vs. 2nd/3rd-line setting?
Do you employ this strategy regardless of the pati...
In terms of how I consider intracarnial vs. system...